z-logo
Premium
ERK / MAPK regulates ERR γ expression, transcriptional activity and receptor‐mediated tamoxifen resistance in ER + breast cancer
Author(s) -
Heckler Mary M.,
Thakor Hemang,
Schafer Cara C.,
Riggins Rebecca B.
Publication year - 2014
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.12797
Subject(s) - mapk/erk pathway , chemistry , receptor , breast cancer , cancer research , microbiology and biotechnology , signal transduction , biology , cancer , biochemistry , genetics
Selective estrogen receptor modulators such as tamoxifen ( TAM ) significantly improve breast cancer‐specific survival for women with estrogen receptor‐positive ( ER +) disease. However, resistance to TAM remains a major clinical problem. The resistant phenotype is usually not driven by loss or mutation of the estrogen receptor; instead, changes in multiple proliferative and/or survival pathways over‐ride the inhibitory effects of TAM . Estrogen‐related receptor γ ( ERR γ) is an orphan member of the nuclear receptor superfamily that promotes TAM resistance in ER + breast cancer cells. This study sought to clarify the mechanism(s) by which this orphan nuclear receptor is regulated, and hence affects TAM resistance. m RNA and protein expression/phosphorylation were monitored by RT ‐ PCR and western blotting, respectively. Site‐directed mutagenesis was used to disrupt consensus extracellular signal‐regulated kinase (ERK) target sites. Cell proliferation and cell‐cycle progression were measured by flow cytometric methods. ERR γ transcriptional activity was assessed by dual‐luciferase promoter–reporter assays. We show that ERR γ protein levels are affected by the activation state of ERK /mitogen‐activated protein kinase, and mutation of consensus ERK target sites impairs ERR γ‐driven transcriptional activity and TAM resistance. These findings shed new light on the functional significance of ERR γ in ER + breast cancer, and are the first to demonstrate a role for kinase regulation of this orphan nuclear receptor.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom